Filter By Cateory

PanKbase AI Pilot Funding Program (PanKbase)

PanKbase plans to offer annual pilot funding opportunities to support the timely adoption of rapid advancements in Artificial Intelligence (AI) and data science into the PanKbase platform. Awardees are expected to share all data and AI products generated through the awarded projects via the PanKbase platform and through close collaboration with the PanKbase team. The priority areas of interest will be updated annually. In 2025, two types of applications will be considered:

  • Partner Programs: Proposals from programs that are interested in partnering with PanKbase to enhance the interoperability and harmonization between their platforms and PanKbase, by leveraging generative AI, large language models (LLMs), and/or retrieval-augmented generation (RAG).
  • Research Teams: Proposals from teams developing foundational models or AI agents of the pancreas with a focus on type 1 diabetes (T1D), as well as AI applications that integrate multimodal data, or enhance the usability, accessibility, or training capabilities of PanKbase.

KEY DATES
Application Due Date:                                  August 31, 2025
Start Date:                                                    November 15, 2025 
Eligibility:                                                      Foreign applications are not eligible

Data Scholars Awards (2025)

A new funding initiative to support the use of existing HIRN datasets and resources to explore unique and innovative hypotheses designed to accelerate breakthroughs and advances in type 1 diabetes (T1D) research.

Key Dates:

Posted Date:
Application Due Date:
Scientific Review:
Start Date:

April 1, 2025
May 1, 2025; November 1, 2025
June 2025; December 2025
August 2025; February 2026

Learn more at:  https://hirnetwork.org/datascholars2025

Please refer to the RFP for details: HIRN RFP Data Scholars Initiative (7444 downloads )

Helmsley Charitable Trust’s Type 1 Diabetes (T1D)

The Leona M. and Harry B. Helmsley Charitable Trust’s (Helmsley) Type 1 Diabetes (T1D) Program aims to support the discovery and development of new therapies to prevent or delay T1D and the identification and validation of biomarkers to predict disease initiation and progression.

T1D is a complex autoimmune disease where insulin-producing beta cells in the pancreas are targeted by immune cells. The predisposing factors, triggers, and other elements that affect disease pathogenesis in humans are not yet fully identified. Understanding these drivers of disease could lead to discoveries of new drug targets, guide intervention strategies to halt the disease, or improve prediction of disease development.

To date most T1D preclinical and clinical research has focused on the role T cells play in disease pathogenesis. However, innate immune cells are the first and most abundant type of immune cells in the pancreas, especially in individuals with T1D. Moreover, data, mostly generated from animal experiments, suggests that these cells might play different roles in T1D: from activating T cells and/or recruiting them to the pancreatic islets, to promoting inflammation or inducing immune tolerance. However, what leads to an increase in innate immune cells in the pancreas during T1D, its significance, and what role these cells play in disease in humans is not yet fully understood.

Learn More HERE

Posted: March 3, 2025
Concept notes due: April 30, 2025
Full grant proposal due: July 30, 2025
Start date: February 2026

New Investigator Gateway Awards for Collaborative T1D Research (R03 Clinical Trial Not Allowed) (RFA-DK-26-009)

The New Investigator Gateway Award in T1D Research is designed to support a robust pipeline of innovative projects and talented new investigators in T1D research. In addition to providing support for preliminary research, the Gateway program provides an opportunity for new Program Directors/Principal Investigators (PD/PIs) to pursue their studies within the intellectual environment of a select number of large, ongoing collaborative research programs. Embedding awardees within an established scientific framework in each of these consortia will provide unique opportunities for New and Early Stage Investigators to increase their understanding of key questions in the field, to network, and to establish unique and potentially long-lasting collaborations that will propel their careers forward. Bringing New and Early Stage Investigators into existing collaborative research networks will also benefit the networks by providing new ideas and perspectives. 

This NOFO is associated with the Special Diabetes Program which funds research on the prevention, treatment, and cure of type 1 diabetes and its complications, including unique, innovative, and collaborative research consortia and clinical trials networks.  

Application due dates:

  • June 26, 2025
  • March 6, 2026
Follow
×

Follow

us on our social networks.

Email: hirnec@coh.org